Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 41, 3233-3237, August 1, 1981]
© 1981 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jung, A.
Right arrow Articles by Courvoisier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jung, A.
Right arrow Articles by Courvoisier, B.

Inhibition by Two Diphosphonates of Bone Lysis in Tumor-conditioned Media1

A. Jung2, B. Mermillod, C. Barras, M. Baud and B. Courvoisier

Centre for the Study of Bone Diseases, Department of Medicine, University Hospital, Geneva, Switzerland

In order to test the effect of diphosphonates in inhibiting bone lysis induced by human tumors, neonatal mouse calvaria are cultured in sterile conditions in different media. Osteolysis is estimated by the amount of 45Ca released from bone to medium, the mice being given injections of 45Ca on their day of birth. An increased bone lysis is observed when calvaria are incubated in the same medium conditioned from cultured tumor fragments. This effect is significantly decreased when the mice have been treated with either ethanehydroxydiphosphonate or dichloromethylenediphosphonate. These experiments represent a first step in estimating the potential effects of different drugs on malignant osteolysis.

1 Work supported by grants from the Swiss Foundation for Grants in Biology and Medicine, by the Swiss League Against Cancer, and by the Intermaritime Foundation.

2 To whom requests for reprints should be addressed, at Clinique Médicale Thérapeutique, Hôpital Cantonal, 1211 Geneva 4, Switzerland.

Received 1/24/80. Accepted 5/ 4/81.




This article has been cited by other articles:


Home page
AM J HOSP PALLIAT CAREHome page
K. Mystakidou, E. Katsouda, E. Parpa, E. Kouskouni, C. Chondros, M. L. Tsiatas, A. Galanos, and L. Vlahos
A prospective randomized controlled clinical trial of zoledronic acid for bone metastases
American Journal of Hospice and Palliative Medicine, January 1, 2006; 23(1): 41 - 50.
[Abstract] [PDF]


Home page
Endocr. Rev.Home page
H. Fleisch
Bisphosphonates: Mechanisms of Action
Endocr. Rev., February 1, 1998; 19(1): 80 - 100.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1981 by the American Association for Cancer Research.